FundedIQ
Health Care

CrannMed

CrannMed aims to eliminate chronic pain, restore mobility, and stop disease progression for patients with knee osteoarthritis. Their solution provides an alternative treatment for this debilitating disease through the development of bioresorbable embolic particles and a balloon occlusion microcatheter.

crannmed.com Dublin, Ireland 11-50 employees
Total raised
$14.8M
Rounds
1
Latest
Series Unknown
Feb 2026

CrannMed aims to eliminate chronic pain, restore mobility, and stop disease progression for patients with knee osteoarthritis. Their solution provides an alternative treatment for this debilitating disease through the development of bioresorbable embolic particles and a balloon occlusion microcatheter.

CrannMed has raised $14.8M across 1 round. Its most recent round was a Series Unknown of $14.8M in Feb 2026. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Feb 26, 2026
Series Unknown
$14.8M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

CrannMed is featured in

Similar companies

Neurent Medical

Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal diseases. It was founded in 2015 by Brian Shields and David Townley in Oranmore, Galway, Ireland.

Series C $74.5M
Bluedrop Medical

It has been estimated that up to 25% of people with diabetes will develop a foot ulcer at some point in their life. One of the main causes is peripheral neuropathy, which results in a patient losing sensation in their feet. Of the millions who develop ulcers every year, hundreds of thousands will require amputation due to infection.

Series Unknown $1.2M
Rockfield Medical Devices

Rockfield Medical Devices is an innovative SME in the area of human centered design process in the medical device industry. The company is led by its founder and has a very strong team made up of several acknowledged experts from the medical device industry and from research and design. Rockfield aims to be a leading innovator in the enteral feeding market globally and strives to achieve exemplary end user satisfaction with their plug and play technologies through innovative design, usability and mobility.

Series Unknown $3.8M
FeelTect

The Tight Alright technology developed by FeelTect is a connected-health device designed to measure and monitor the pressure beneath a bandage during compression therapy. This innovative device is primarily targeted towards the millions of individuals globally who suffer from venous leg ulcers (VLUs). Compression therapy has been proven effective for treating VLUs; however, if the compression is too loose, it becomes ineffective, and if it is too tight, it can pose risks to the patient's health.

Series Unknown $7.3M
ProVerum Medical

ProVerum Medical is a healthcare company that creates new therapies for benign prostatic hyperplasia (BPH). The company's ProVee System is a minimally invasive implant designed to unblock the urethra without the need for cutting, heating, or removing tissue.

Series B $80.0M
CroíValve

CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation

Series Unknown $2.9M
Novus Diagnostics

When a patient is critically ill, giving their doctor the right information at the right time can mean the difference between life and death. At Novus Diagnostics, we are developing ground-breaking diagnostics technologies to provide rapid answers right at the patient’s bedside. Our first product, SepTec, will help tackle the global challenge of sepsis which kills more than 11 million people every year. Our technology platform brings together novel electrochemical sensors, centrifugal microfluidics and automated sample processing and analysis to diagnose and characterise a blood stream infection within 15 minutes; enabling earlier lifesaving targeted treatment. We are a young, driven company working to solve a major global health challenge. We are building a team of people who are excited by this challenge and committed to making a real difference through their work.

Seed $4.7M
SISU Aesthetic Clinic

SISU is a collection of doctor-led, patient-centric aesthetic medical clinics.

Series Unknown $15.0M
Vida Care

Vida Care offers patients the opportunity to easily schedule various routine tests such as blood, cholesterol, cortisol, diabetes, thyroid, hormones, colon cancer, and STIs, with the convenience of receiving results within 48 hours. This program allows patients immediate access to preventative health screening.

Series Unknown $1.0M
LaNua Medical

LaNua Medical develop disruptive image-guided technologies providing safe and effective endovascular solutions.

Seed $6.3M
NUA Surgical

NUA Surgical is an award-winning start-up based at the Innovation Hub, Galway on the West Coast of Ireland. The company has invented the patented and specialized surgical retractor to make C-Sections a safer and superior surgery.

Series A $6.9M
SymPhysis Medical

SymPhysis' Medical will likely foster inventive innovations that treat a scope of ongoing infections, putting the patient involvement with the cutting edge of our plan answers for work on personal satisfaction. About SymPhysis MedicalSymPhysis Medical's rising innovation, releaze, is a waste innovation to treat a typical confusion of late-stage tumors, harmful pleural emission (MPE). MPE causes significant windedness and chest torment in up to 15% of patients with malignant growth.

Series Unknown $2.4M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.